Baird Medical Investment Holdings Business Summary

Baird Medical Investment Holdings Ltd (BDMD) is a medical technology firm specializing in the design, manufacture, and sale of minimally invasive microwave ablation (MWA) systems for tumor treatment. The company generates revenue through the sale of proprietary MWA hardware—including microwave generators and specialized needles for thyroid, liver, and breast procedures—and the distribution of third-party medical devices such as ventilators and catheters. Its operations are divided into two primary segments: Proprietary MWA Devices and General Medical Device Sales. As the first company to secure a Class III medical device registration for thyroid MWA in China, Baird Medical maintains a dominant position in its home market while expanding into the U.S. and Japan. It competes directly with medical equipment providers such as Accuray Inc., Sensus Healthcare, and QT Imaging, positioning itself as a high-margin, specialized leader in the thermal ablation niche relative to broader medical instrument conglomerates. The company was founded by Haimei Wu, who serves as Chairwoman and CEO, leveraging over two decades of industry experience and her previous success founding Betters Medical. The executive suite includes U.S. Subsidiary CEO Mark Saxton, a commercial veteran with a 25-year pedigree at VNUS Medical and NeuroPace, and CTO Rongjian Lu, who oversees technical R&D. Financial operations are managed by Acting CFO Jie Li, while Quan Qiu serves as Chief Administrative Officer. The board is strengthened by independent director Joseph Douglas Ragan III, the current CFO of Paper Excellence Group, and the company is backed by strategic partner Stonewood Key Capital, which entered a major global commercialization agreement with Baird in January 2026.